MedTrace Logo

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

NCT00718809 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-06-10

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Conditions

  • Invasive Thymoma and Thymic Carcinoma
  • Recurrent Thymoma and Thymic Carcinoma
  • Stage III Thymoma
  • Stage IVA Thymoma
  • Stage IVB Thymoma

Interventions

DRUG

saracatinib

Given orally

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Patrick Loehrer · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-08-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00718809 on ClinicalTrials.gov